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The recorded growth in infection by multidrug resistant bacteria necessitates prompt
efforts toward developing alternatives to antibiotics, such as bacteriophage therapy.
Immuno-compromised patients with diabetes mellitus are particularly prone to foot
infections by multidrug resistant Klebsiella pneumoniae, which may be compounded by
chronic osteomyelitis. Bacteriophage ZCKP1, isolated from freshwater in Giza, Egypt,
was tested in vitro to evaluate its lytic activity against a multidrug resistant K. pneumoniae
KP/01, isolated from foot wound of a diabetic patient in Egypt. Characterization of
ZCKP1 phage indicated that it belonged to theMyoviridae family of bacteriophages with
a ds-DNA genome size of 150.9 kb. Bacteriophage ZCKP1 lysed a range of osteomyelitis
pathogenic agents including Klebsiella spp., Proteus spp. and E. coli isolates. The
bacteriophage reduced the bacterial counts of host bacteria by≥2 log10 CFU/ml at 25
◦C,
and demonstrated the ability to reduce bacterial counts and biofilm biomass (>50%)
when applied at high multiplicity of infection (50 PFU/CFU). These characteristics make
ZCKP1 phage of potential therapeutic value to treat K. pneumoniae and associated
bacteria present in diabetic foot patients.
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INTRODUCTION
Klebsiella pneumoniae belongs to the Enterobacteriaceae family. It primarily affects patients with
compromised defenses to cause severe complications. It is a particular problem for patients
with diabetes mellitus leading to “diabetic foot” infections and osteomyelitis (Podschun and
Ullmann, 1998). Once infection is established K. pneumoniae forms a biofilm that enables
evasion of the host’s defenses (Akers et al., 2014; Gupta et al., 2016). Moreover, phagocytosis by
polymorphonuclear granulocytes is dramatically hindered, as K. pneumoniae possesses an outer
protective polysaccharide capsule, a key determinant of their subsequent pathogenicity. The capsule
suppresses complement components, particularly C3b (Domenico et al., 1994; Diago-Navarro
et al., 2014). Among many other pathogenicity factors, bone adherence is attributed to adhesin
production that may be fimbrial, or non-fimbrial (Malhotra et al., 2014). Staphylococcus aureus is
considered the most frequently implicated bacterium in cases of diabetic foot infection (Richard,
2011) but recent data indicate that K. pneumoniae is responsible for approximately 21.7% of
cases (Mukkunnath et al., 2015. With rising numbers of diabetes patients and the severity of foot
osteomyelitis complications, this represents a considerable economic burden on health providers,
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notwithstanding the suffering of the individuals affected.
In the past, K. pneumoniae was primarily associated with
pulmonary and urinary infections, and was only relatively
recently recognized as a significant cause of foot osteomyelitis
(Dourakis et al., 2006; Prokesch et al., 2016).
Foot osteomyelitis is a common and serious problem in
diabetic patients resulting chiefly from peripheral neuropathy
or, less commonly, by vasculopathy and wound healing
impediments (Grayson et al., 1995). It occurs in approximately
two thirds of cases of diabetic foot patients (Grayson et al.,
1995). K. pneumoniae is able to migrate to bone tissues
haematogeneously (derived from or transported by blood) or
contiguously from areas of local infections in the feet of
diabetic patients (Mathews et al., 2010; Rana et al., 2013).
If not effectively treated, viable cells of the infectious agent
can be trapped in the devitalized bone and thus evade
host defenses, and eventually cause chronic osteomyelitis
(NADE, 1975; Ross et al., 2003; Calhoun and Manring,
2005).
In addition to the virulence characteristics described, the
emergence of MDR K. pneumoniae strains, resistant to the
last-line antibiotic treatment colistin, is a major concern (Kidd
et al., 2017). Resistance arises from mutations of the mgrB
gene, which are stably maintained in Klebsiella populations,
from which resistance can be disseminated, in addition to
plasmid mediated resistance due to mcr-1 and mcr-2 genes
(Cannatelli et al., 2015). With the advent of the post-antibiotic
era, severe cases of osteomyelitis may require more frequent
surgical intervention in the form of resection of the infected and
necrotic bone (Sanchez et al., 2013). It is therefore vital to seek
alternative therapies to treat K. pneumoniae and other bacterial
infections especially in developing countries (Nagel et al., 2016).
Bacteriophage therapy is a good candidate and has been shown,
using mice as animal models, to provide significant protection
against respiratory and other infections caused by K. pneumoniae
such as liver abscesses and bacteremia (Chhibber et al., 2008;
Hung et al., 2011). Bacteriophage therapy has also been used to
treat K. pneumoniae infected burn wound infections, in mice
(Malik and Chhibber, 2009). Intranasal administration of lytic
bacteriophage reduced the bacterial burden of K. pneumoniae
in the lungs of mice (Cao et al., 2015). Other studies have
characterized a number of diverse lytic bacteriophages to K.
pneumoniae belonging to different families and demonstrated
their potential in vitro (Bogovazova et al., 1991; Kesik-Szeloch
et al., 2013; Hoyles et al., 2015). Bacteriophage therapy is
regarded as a simple, safe and highly effective alternative to
counter the rising problems associated with multidrug resistant
bacteria (Qadir, 2015; El-Shibiny et al., 2017). Here we evaluate
the lytic activity of bacteriophage ZCKP1 isolated from an
environmental freshwater source in Egypt against a MDR
K. pneumoniae KP/01 isolated from the foot of a diabetic
patient.
Abbreviations: BIMs, bacteriophage insensitive mutants; IC, phage infective
centers; MOI, multiplicity of infection; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide.
MATERIALS AND METHODS
Bacterial Strains and Growth Media
K. pneumoniae KP/01, used as a host for bacteriophage infection,
was isolated from a human clinical diabetic-foot sample from a
male patient in May 2016 and identified by National Institute
of Diabetes using the VITEK method for identification (Cairo,
Egypt). Other clinical isolates of K. pneumoniae (n= 21), Proteus
mirabilis (n = 18) and E. coli (n = 15) were also isolated
by National Institute of Diabetes, for bacteriophage host-range
analysis, from wound infection samples and provided to the
microbiology research lab at Zewail City. Isolates were kept in
tryptone soy broth (TSB; Oxoid, England) containing (w/v) 20%
of glycerol, at −80◦C. In the following experiments, bacterial
strains were grown on tryptic soy agar (TSA; Oxoid, England)
overnight, and isolated colonies of bacteria were grown at 37◦C,
in TSB, to reach OD600 approximately 0.3.
Bacterial Identification Using PCR Specific
Primers and Gel Electrophoresis
PCR amplification was performed to confirm the identity of
the K. pneumoniae isolate (KP/01) using specific primers for
16s RNA gene (forward primer: 5′-ATTTGAAGAGGTTGCAAA
CGAT-3′ and reverse primer: 5′-TTCACTCTGAAGTTTTCT
TGTGTTC-3′; Woese and Fox, 1977; Woese et al., 1990). Thirty
cycles were performed at denaturation temperature of 95◦C for
30 s; annealing at 58◦C for 60 s and extension at 72◦C for 1min
looking for a PCR product of 133 bp length using an Applied
Biosystems thermal cycler (Cady et al., 2012). The PCR product
was run on a 1% (w/v) agarose gel to identify its size.
Antibiotic Sensitivity Test
K. pneumoniaeKP/01 strain was subjected to antibiotic resistance
evaluation against a set of antibiotic discs including: tigecycline
(TGC; 15 µg), imipenem (IPM; 10 µg), piperacillin-tazobactam
(TZP; 100/10 µg), levofloxacin (LEV; 5 µg), linezolid (LZD;
30 µg), ceftazidime (CAZ; 30 µg), and cefepime (FEP; 30
µg) all from Oxoid (England). Antimicrobial sensitivity testing
was performed for strains of K. pneumoniae, E. coli and P.
mirabilisby using the disk diffusion methods in accordance with
National Committee for Clinical Standards guidelines (Clinical
and Laboratory Standards Institute, 1999). The antibiotics chosen
are usually used for the treatment of diabetic foot infections
in National Institute of Diabetes, due to their efficacy against
members of the Enterobacteriaceae.
Bacteriophage Isolation, Amplification and
Purification
Bacteriophages were isolated from environmental water samples
from freshwater in El- Maryoteyya-Haram area, Giza, Egypt.
K. pneumoniae (KP/01) used as a bacterial host upon which the
clear plaquing phage were selected for further characterization.
The bacteriophage plaques were purified by repeated single
plaque isolation using sterile micropipette tips (Adams, 1959).
All isolated bacteriophages were amplified in liquid culture (TSB)
and the lysates were centrifuged at 6,400× g for 15min at 4◦C to
remove remaining bacterial cells and debris (Marcó et al., 2012).
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The supernatant containing phages was then centrifuged for 1 h
15,300 × g at 4◦C. The pellet was resuspended in SM buffer
(100mM MgSO4.7 H2O; 10mM NaCl; 50mM TrisHCl; pH 7.5)
and filtered using 0.22µm syringe filters (Chromtech, Taiwan).
Bacteriophage titers were determined using double-agar overlay
plaque assays (Mazzocco et al., 2009).
Examination of Bacteriophage Morphology
by Electron Microscopy
The morphology of bacteriophage ZCKP1 was investigated
using transmission electron microscopy at the National Research
Center (Cairo, Egypt). Formvar carbon coated copper grids
(Pelco International) were immersed into phage suspension, the
phage were fixed using glutaraldehyde (2.5% v/v), washed and
stained using 2% phosphotungstic acid (pH 7.0). After drying,
grids were examined using a transmission electron microscope
(JEOL 1230).
Pulsed Field Gel Electrophoresis (PFGE)
DNA was prepared from bacteriophage ZCKP1 (1010 PFU/ml)
to determine the genome size by pulsed field gel electrophoresis
(PFGE; Senczek et al., 2000). Briefly, bacteriophage suspended
in agarose plugs were digested with lysis buffer (0.2% w/v SDS
[Sigma]; 1% w/v N-Lauryl sarcosine [Sigma]; 100mM EDTA;
1 mg/ml Proteinase K [Fischer Scientific]), overnight at 55◦C.
Following washing 2mm slices of agaraose containing DNAwere
inserted into the wells of a 1% w/v agarose gel. The gel was run
by using a Bio-Rad CHEF DRII system, in 0.5 X Tris-borate-
EDTA, for 18 h at 6 V/cm with a switch time of 30 to 60 s. The
size of the genome was determined by comparison to standard
concatenated lambda DNAmarkers (Sigma Aldrich, Gillingham,
UK).
Phage DNA Sequencing
Genomic DNA was prepared from phage ZCKP1 (1010 PFU/ml)
lysates by proteinase K treatment (100µg/ml in 10mM EDTA
pH 8) followed by resin purification using the Wizard DNA
kit (Promega, UK) following the manufacturer’s instructions.
DNA sequencing was performed using the Illumina MiSeq
platform. The data consisted of 3.1 million paired-end sequence
reads of 250 bp in length. Initial processing of the raw data
and de novo assembly was performed using CLC Genomics
Workbench version 11.0.1 (Qiagen, Aarhus, Denmark). ORFs
were predicted from PHASTER and manually curated (Arndt
et al., 2016). Nucleotide sequences appear under the GenBank
accession number MH252123.
Lytic Profiles of Isolated Bacteriophages
Using double-agar overlay plaque assays (Mazzocco et al., 2009),
the lytic profile of phage ZCKP1 and other isolated phages was
determined against a clinical isolate panel when spotted phage
concentrations were not<109 PFU/ml [34]. The experiment was
performed using log phase bacteria. The panel included bacteria
that cause osteomyelitis, including K. pneumoniae, P. mirabilis
and E. coli. The lytic activity of bacteriophages was determined
based on plaques of clear lysis. If≥20 plaques were produced, the
tested bacteria were regarded as being sensitive to the phages.
Efficiency of Plating
Bacteriophage ZCKP1 was tested in triplicate over eight decimal
dilutions against all the susceptible bacterial strains lysed in
the spot assays as previously described (Viazis et al., 2011).
Conditions of these experiments were the same as spot test using
log-phase bacteria. Thus, 200 µl of all bacterial isolates were
added to top agar, and different dilutions of phages were spotted
on petri dishes. The plates were incubated overnight at 37◦C.
Next day, EOP was estimated as the average PFU on target
bacteria/average PFU on host bacteria.
Determination of the Frequency of
Bacteriophage Insensitive Mutants
The frequency of the emergence of bacteriophage insensitive
mutants (BIMs) was estimated as previously described (O’Flynn
et al., 2004). Phage ZCKP1 was mixed with bacterial host strains
confirmed to be susceptible to the bacteriophage including strains
of K. pneumoniae, P. mirabilis, and E. coli at anMOI of 100. After
10min of incubation at 37◦C, the suspension was serial diluted
and spotted using double-agar overlay plaque assays. Plates were
incubated overnight and BIM was calculated correspondingly by
dividing bacterial viable counts remained after phage infection by
initial viable counts. Experiments were conducted in triplicate.
One Step Growth Curve
One step growth curves were performed as previously described
(Hyman and Abedon, 2009). Briefly, KP/01 strain was grown
at concentration of 108 and mixed with bacteriophage at
multiplicity of infection of 1 and incubated at 37◦C for 2 h.
Directly after infection and every 10min, aliquots of 200 µl were
withdrawn and divided into two volumes of 100 µl. Chloroform
was added to one of two volumes with a concentration of 1%
(v/v); to set intracellular phages free while other 100 µl was left
with no chloroform addition. After serial dilution, phage titer was
estimated by spotting on top agar using double-layer method.
Three replicates were conducted for each time interval.
Bacteriophage Potency Against Planktonic
Cells
The survival lysis characteristics of phage ZCKP1 were estimated
KP/01 in the presence of ZCKP1 phage at multiplicities of
infection of 0.1, 10 and 100 PFU/CFU was estimated in
comparison to bacterial control at a temperature of 37◦C (phage-
free samples; Armon and Kott, 1993). Phage infective centers
(IC) and plaque forming units (PFU) were also estimated, at
different time intervals (0, 5, 10, 20, 30, 40, 60, 90, 120, and
180min). IC is the amount of free phage particles released from
the bacterial cells, without the need to add chloroform, while
PFU refers to the number of nascent phage both inside and
outside the bacterial cell. Briefly, two flasks were filled with
either bacterial culture at a given concentration (control) or with
bacterial culture at the same concentration and bacteriophage
matching the desired MOI (Test). At every time interval, the
concentration of bacterial control (B), bacterial survival (BS) IC,
and PFU were simultaneously estimated. Bacterial concentration
were determined using the Miles and Misra method (Miles et al.,
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1938), while phage concentration was estimated using double-
agar overlay plaque assays by adding chloroform to the aliquot
to be estimated in case of PFU determination, or not adding
chloroform to calculate the IC.
Bacteriophage ZCKP1 was added to K. pneumoniae KP/01 in
log-phase of growth, at 25◦C, at an MOI of 1. Bacterial survival,
number of infective centers, and number of plaque forming units
were estimated periodically at different time intervals (0, 8, 24,
32, and 48 h).
Bacteriophage Activity Against Established
Biofilms of K. pneumoniae
The activity of ZCKP1 against established biofilms of KP1/01 was
examined using a modification of previously described protocols
(Cerca et al., 2005; Pettit et al., 2005). One hundred microliter
aliquots of K. pneumoniae KP/01 (5 × 106 CFU/ml) in 96-well
flat-bottomed polystyrene microtitre plate (Sigma Aldrich) were
incubated for 24 h at 37◦C. Unattached planktonic cells were
carefully removed. The number of bacterial cells in a biofilm
per well were estimated to be 107 CFU after 24 h (Mottola
et al., 2013). Using different MOIs (5, 10, and 50), 100 µl
aliquots of phage ZCKP1 diluted in TSB were added to each
well, 1 day after biofilm establishment. Other wells received an
equivalent amount of TSB as positive controls. In a parallel
experiment, phage was introduced to wells every 4 h carefully
replacing the previous suspension (containing TSB, planktonic
cells and released phages) without disturbing the established
biofilms. The biomass of preformed biofilms was quantified by
staining with crystal violet (0.2% w/v). Following washing to
remove excess dye with PBS, the crystal violet was solubilized in
ethanol (95%). The absorbance was measured using a microplate
reader at OD600 (Biotek, USA). The bacterial counts in biofilms
were estimated using an MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assay (Serva Electrophores,
Germany) as described by Cady et al. (2012). The absorbance was
then measured at 570 nm at 4, 12, and 24 h, using a microplate
reader (BioTek, USA). Control and test samples were assayed in
triplicate.
Bacteriophage pH and Temperature
Stability
The temperature stability of phage ZCKP1 (1010 PFU/ml) was
evaluated at 45, 55, 65, 75, 85, and 95◦C, at 10min intervals,
over 1 h in adjusted water bath incubator. Immediately after
incubation, serial dilutions of phage were spotted in triplicate,
using standard double layer technique; on a lawn of host strain
(KP/01) to estimate phage titers as previously described (Capra
et al., 2004; Hammerl et al., 2014).
The bacterial counts of ZCKP1 at different pH values (5, 6,
7, 8, and 9) was determined after 1 h incubation, followed by
determining the phage titer as previously described (Hammerl
et al., 2014). Different pH values were achieved in SM phage
buffer to maintain comparative conditions.
Statistical Analysis
In all data sets, test and control sets were compared using
Student’s t-test. A significance level of 0.05 was applied in
all cases. Analytical statistics were undertaken using GraphPad
PRISM version 7.00 for Windows (GraphPad Software, La Jolla,
USA).
RESULTS
Klebsiella Identification and Sensitivity to
Antibiotics
The identity of the KP/01 strain was confirmed to be K.
pneumoniae by PCR, by the presence of 133 bp band
corresponding to conserved region in 16s RNA gene of K.
pneumoniae, following amplification with the specific primers.
The antibiotic sensitivity of K. pneumoniae isolate KP/01 was
tested using the disc diffusionmethod and the results showed that
K. pneumoniae isolate KP/01 was sensitive to tigecycline (TGC),
imipenem (IPM) and piperacillin-tazobactam (TZP) but resistant
to levofloxacin (LEV), linezolid (LZD), ceftazidime (CAZ) and
cefepime (FEP).
Bacteriophage Isolation
Bacteriophages were isolated from freshwater near the pyramids
of Egypt in Giza. Selection of the bacteriophage was undertaken
upon serial passage according to their ability to lyse a broad
range of K. pneumoniae isolates and other pathogens causing
osteomyelitis, generate reproducible clear zones of lysis, produce
hallow zones around lysis zones indicative of exopolysaccharide
depolymerase activity and capable of replication to produce high
titers on the selected host with respect to time. Bacteriophage
ZCKP1 fulfilled these criteria.
Morphology of Lytic ZCKP1 Phage
Electron microscopy revealed that ZCKP1 had an icosahedral
head and contractile tail with collar, and base plate, and
therefore typical of phages belonging to the family ofMyoviridae
(Figure 1). The proportions of the phage head and tail length
were also typical of the Myoviridae with the head size being 80
± 0.7 nm while tail length was calculated to be 138.5± 2.5 nm.
Phage Genome
Bacteriophage ZCKP1 contains a double-stranded DNA genome
estimated to be 160 kbp by PFGE, which is comparable to values
indicated by International Committee on Taxonomy of Viruses
(ICTV) for bacteriophages belonging to the Myoviridae family.
DNA sequencing of the phage DNA enabled de novo assembly
and accurate size determination of a circular permuted genome
of 150,925 bp with a G + C content of 39.1%. The genome
contained 267 open reading frames, the majority of which
are hypothetical proteins or recognized in BLASTP database
searches as phage proteins without any ascribed function.
Reading frames for which putative functional information could
be ascribed to the products appear in Supplementary Table 1.
Notably these include the phage structural proteins, nucleotide
metabolism and components of the replication machinery
that are conserved amongst Myoviridae infecting hosts within
the Enterobacteriaceae. Of interest are enzymes that have the
potential to modify infected cell surface polysaccharides that may
impede superinfection. These include an O-antigen biosynthesis
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FIGURE 1 | Transmission electronmicroscopic image of phage ZCKP1.
protein, a glycosyltransferase and a wcaM superfamily protein
associated with colonic acid biosynthesis clusters present in
Enterobacteriaceae that feature exopolysaccharide production.
Four genes encoding proteins related to tellurite resistance are
present. Tellurite resistance is frequently used for selection
in culture isolation media but is not used for antimicrobial
therapy. The genes are thought to contribute to colicin and
phage resistance (Taylor and Summers, 1979), whichmay provide
reasons for their presence in phage ZCKP1 in that colicin
resistance will provide a selective advantage to the phage infected
cell and phage resistance to prevent superinfection. Also of note
the phage encodes a member of the hydrolase 2 superfamily
implicated in bacterial cell wall hydrolysis. The nearest database
phage sequence was PHAGE_Escher_phAPEC8 that infects avian
pathogenic E. coli and is also amember of theMyoviridae (Tsonos
et al., 2012).
Bacteriophage Host Range and Efficiency
of Plating
The host range of five different phages isolated from freshwater,
including phage ZCKP1were tested on bacteria that were isolated
from diabetic patients suffering from osteomyelitis. The ZCKP1
phage was capable of producing lysis zones (≥20 plaques) on
15 out of 21 K. pneumoniae isolates, 5 out of 18 P. mirabilis
isolates and 9 out of 30 E. coli isolates, while other phages
did not display a comparable spectrum of activity against the
K. pneumoniae isolates (Table 1). A range of EOP for ZCKP1
phage was observed against different species of Enterobacteriacae
TABLE 1 | Lytic activity of isolated phages against K. pneumoniae and other




ZCKP1 P2 K4 EC4 P9
K. pneumonia
(21 isolates)
15 3 5 1 2
P. mirabilis
(18 isolates)
5 5 0 0 8
E. coli
(30 isolates)
9 0 0 2 0




















(Supplementary Table 2). For K. pneumoniae seven phages
demonstrated EOPs similar to the multidrug resistant host
strain. For P. mirabilis, all susceptible strains showed EOP
<0.1, whereas for E. coli six strains supported replication with
EOPs approaching that of the permissive K. pneumoniae hosts
(Table 2).
Frequency of BIMS
BIMs were recovered following high multiplicity infections (100)
of host bacteria K. pneumoniae, P. mirabilis and E. coli with
bacteriophage ZCKP1 at 37◦C. Mutational frequencies of 7.5 ×
10−5± 1.7× 10−4 and 3.7× 10−5± 6.8× 10−5 were determined
for Klebsiella and E. coli, respectively where K. pneumoniae KP1
alone exhibited a lower frequency of 5× 10−6 ± 4.04× 10−6.
In vitro Characterization of Phage ZCKP1
A single-step growth curved demonstrated bacteriophage virions
were naturally released from bacterial cells after 30min: the latent
period which is the time taken for phages to be assembled and
released after infection. However, viruses were assembled 10min
before. This was indicated by eclipse period that was estimated
to be 20min, as chloroform aids new phage particles to free from
bacterial cell wall (Figure 2). Burst size was estimated to be∼110
virions per single bacterium.
The infection and lysis characteristics of phage ZCKP1 were
estimated at different MOIs, over a period of 3 h (Figures 3A–C)
in a growing culture of K. pneumoniae KP/01 (Figures 3A–C).
K. pneumoniae KP/01 was lysed by phage ZCKP1 at each MOI
tested but the MOI of 100 reduced the viable bacteria from 9.0
log10 CFU/ml to below the limit of detection at 37
◦C by 2 h
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FIGURE 2 | Single step growth curve. Gray dashed line represents nascent
phage without chloroform addition (PFU/ml), while the black line represents
phages released after chloroform addition (PFU/ml).
(Figures 3A–C). Under these circumstances the reductions in
bacterial count were not accompanied by a measurable rise in
phage titer (Figure 3C). Phage replication was observed at lower
MOI, which coincided with the commencement of the fall in
viable count.
Bacteriophage Activity Against K.
pneumoniae Established in Biofilms
A single application of ZCKP1 to established biofilms of
K. pneumoniae KP/01 resulted in a reduction crystal violet
stainable biofilm content (P < 0.01; Figure 4A) and the
percentage of viable cells observed by MTT staining (P
< 0.01; Figure 4C) after 4 h. The most effective treat
represented the highest MOI (50 PFU/CFU). However,
following this disruption there was recovery in biofilm
estimates accompanied by a recovery in cell viability. Multiple
treatments of phage ZCKP1 on established K. pneumoniae
KP/01 biofilms at 4 h intervals resulted in significant reductions
in biofilm content and prevented the recovery of cell viability
throughout the 24 h period of the experiment (P < 0.01;
Figures 4B,D).
Bacteriophage Temperature and pH
Stability
The stability of phage ZCKP1 at different temperatures and
pH values was investigated (Figures 5A,B). Phage titers were
stable, at approximately 109 PFU/ml, for 1 h at temperatures
of 45 and 55◦C. The phage titer decreased after 40min at
65◦C to 108 PFU/ml, and continued to decline below 107
PFU/ml after 1 h. A significant decline (P < 0.005) was
observed when phages were incubated at 75 and 85◦C. However,
phage could still be recovered after 1 h at 75◦C at a titer of
103 PFU/ml. Phage could not be recovered after 40min at
85◦C. Acidic pH of <6 significantly (P < 0.005) reduced the
phage stability after 1 h. The optimum stability was observed
to be pH 6 but persisted at alkaline pH values to pH 9
(Figure 5B).
FIGURE 3 | In vitro activity of phage ZCKP1 at 37◦C. Panels show bacterial
counts and phage titers of K. pneumoniae KP/01 infected with ZCKP1 at: (A)
MOI 0.1; (B) MOI 1; (C) MOI 100. Black solid line represents viable count of K.
pneumoniae KP/01 infected with phage (CFU/ml); Gray solid line represents K.
pneumoniae KP/01 uninfected control (CFU/ml); black dashed line represents
phage infective centers (PFU/ml) and gray dashed line represents nascent
phage (PFU/ml).
DISCUSSION
K. pneumoniae is an enteric pathogen that causes pneumonia
and wound infections (Podschun and Ullmann, 1998). The
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FIGURE 4 | Phage treatments of K. pneumoniae KP/01 biofilms. Panels (A) and (B) show the effect of phage treatment on preformed biofilms determined by crystal
violet staining and solubilization estimates of biomass: (A) single treatment with phage ZCKP1; (B) with multiple treatments with phage ZCKP1 using different MOIs.
White columns represent untreated control; light gray columns represent a starting MOI of 5; dark gray columns represent a starting MOI of 10 and solid black
columns represent a starting MOI of 50. Panels (C) and (D) show bacterial counts in biofilms determined using an MTT assay, (C) single treatment with phage ZCKP1
bacteriophage or (D) with multiple treatments with phage ZCKP1 bacteriophage using different MOIs: Light gray columns represent a starting MOI of 50; dark gray
columns represent a starting MOI of 10 and solid black columns represent a starting MOI of 5. *P < 0.01 (brackets specify comparisons between groups).
effectiveness of antibiotics to treat such infections has been
reduced significantly in recent years due to the increasing
numbers of antibiotic-resistant bacteria, and as a result morbidity
and mortality remain high. Antibiotic resistance is a growing
public health threat for which the use of bacteriophage as
an alternative to antibiotics may be considered to combat
MDR infections. In particular phage therapy has also been
considered a promising approach to eliminate diabetic foot
ulcer after infection by MRSA in human subjects (Fish
et al., 2016). In order to get the maximum benefits of
bacteriophage based therapies, it is important to determine the
characteristics of individual bacteriophages so that treatments
can be tailored for the situation where treatment is to be
applied. Moreover, it is crucial to ensure that phages selected
do not have the capacity to transfer resistance or pathogenic
traits to the resident microbiota (Abedon and Thomas-Abedon,
2010).
Antibiotics that were previously effective in the elimination
of diabetic foot infections are now less effective. The K.
pneumoniae KP/01 isolate recorded here shows resistance to
levofloxacin, fluoroquinolone andwas identified as a ceftazidime-
resistant K. pneumoniae (CSKP). Ceftazidime is a cephalosporin
antibiotic that can be degraded by extended spectrum beta
lactamases (ESBL) that include SHV, TEM, CTX and YOU types
(Sougakoff et al., 1988; Urban et al., 1994). K. pneumoniae
KP/01 also showed resistance to the cephalosporin cefepime.
As a clinical multiple drug resistant bacteria the KP/01
isolate was an ideal host for this study (Sougakoff et al.,
1988).
Both morphological analysis and genome size confirmed
that bacteriophage ZCKP1 belonged to the Caudovirales order
with typical features of Myoviridae. It had an icosahedral
head, a contractile tail with base plates showing tail fibers
and spikes in addition to a collar. The genome of 151 kb,
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FIGURE 5 | The stability of phage ZCKP1 at (A) different temperatures (45◦C:
circle, 55◦C: square, 65◦C: triangle, 75◦C: inverted triangle and 85◦C:
diamond) and (B) pH values. Results are shown as means ± Standard error.
differs in size to the 45 kbp of KLPN1 phage previously
reported as isolated against K. pneumoniae (Hoyles et al.,
2015). Bacteriophage ZCKP1 demonstrated a broad lytic
profile covering a variety of bacterial pathogens including
K. pneumoniae, Proteus and E. coli that all contribute to
osteomyelitis cases and were isolated from patients with “diabetic
foot.”
In vitro studies of potential therapeutic bacteriophages ensures
only the most effective phages progress to clinical trials based
on their capability to lyse pathogens in planktonic and biofilm
formations with wide host range coverage. Phage ZCKP1 was
shown to be highly effective at reducing K. pneumoniae counts
in vitro and proved to be stable at high temperatures and over
a wide pH range. Phage ZCKP1 was also effective against other
members of Enterobacteriacae that cause osteomyelitis, which
contributes to the therapeutic potential. With the application
of high concentrations of bacteriophages (MOI of 100), ZCKP1
was demonstrated to reduce K. pneumoniae without producing
new phages. This is an established phenomenon called “lysis
from without,” where many phages become absorbed to bacterial
cells causing lysis without release of new phage (Abedon, 2011).
In addition, a single high dose applied in a clinical situation
may enable the human immune system to overcome reduced
numbers of pathogens by working synergistically with the phage.
Even with lower doses of phage, the rate of development of
resistance to bacteriophages is approximately 10-fold lower than
the rate of the development of antibiotic resistance (Carlton,
1999). The conditions of application and the influence of
immune system can vary so the action of a particular phage
must be considered before therapeutic use (O’Flynn et al.,
2004; Lu and Koeris, 2011). In this context the mutation
frequencies determined at high MOI applications would dictate
the use of phage cocktails, and possibly the availability of
reserve phage. Developing a cocktail of isolated lytic phages
may increase the efficacy of bacteriophages to lyse multiple
hosts and reduce the frequency that resistant strains may
emerge.
Klebsiella are able to form thick biofilms on tissues and
on medical implants making them more resistant than
free-living planktonic cells to antibacterial agents and have
reduced susceptibility to antibiotics (Calhoun and Manring,
2005). Phage ZCKP1 treatment of K. pneumoniae KP/01
biofilms was shown to be an effective method for biofilm
reduction, although repeated treatments were required
to prevent regrowth. Reductions in biofilm biomass have
been attributed to the action of a soluble exopolysaccharide
depolymerase (Cornelissen et al., 2011). These enzymes
have the ability to disrupt the capsule of Klebsiella making
it more susceptible to antibacterial agents (Hughes et al.,
1998; Kesik-Szeloch et al., 2013). The nucleotide sequence
of phage ZCKP1 revealed enzyme activities consistent with
polysaccharide modification, However, the presence of wcaM
could influence exopolysaccharide structure to adversely affect
biofilm integrity when embedded bacteria become phage
infected.
Previously reported phage treatments of K. pneumoniae
biofilms include: a phage belonging to the Podoviridae family
(Chhibber et al., 2013); a Siphoviridae named bacteriophage
Z (Jamal et al., 2015) and Myoviridae phages (Kesik-Szeloch
et al., 2013). Of these, the Myoviridae are likely the most
promising as they represent virulent bacteriophage that do not
mobilize and transfer genetic information. The gene sequence
of phage ZCKP1 suggests that it does indeed fall into this
category. Four genes associated with tellurite resistance were
observed but are not used for antimicrobial therapy. Tellurite
resistance is often associated with colicin and phage resistance
phenotypes (Taylor and Summers, 1979), and likely extends
this advantage to the virus infected cell as insurance against
superinfection.
CONCLUSION
Phage ZCKP1 has been fully characterized in vitro and shows
excellent potential to be used as a therapeutic agent against
K. pneumoniae infections of diabetic foot. It can reduce
the bacterial pathogen in both planktonic and biofilms and
is extremely stable over a range of pH and temperatures.
Therapeutic trials are needed to confirm its potential
in vivo.
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